» Articles » PMID: 1310144

Differential Activation of Intracellular Effector by Two Isoforms of Human Neurokinin-1 Receptor

Overview
Journal Mol Pharmacol
Date 1992 Jan 1
PMID 1310144
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

Two isoforms of the human neurokinin-1 receptor were cloned and characterized in heterologous expression systems of mammalian cell culture and Xenopus oocytes. The two isoforms differ only in the length of the encoded polypeptide. The peptide-binding properties of the long form of human neurokinin-1 receptor are consistent with those of the native neurokinin-1 receptor of mammalian tissues, where substance P is the most potent agonist. Peptide agonists elicit an oscillating current in Xenopus oocytes expressing the long form. In contrast, the short form of human neurokinin-1 receptor expressed in COS cells binds substance P with an apparent affinity at least 10-fold lower than that of the long form, and it elicits the electrophysiological response only weakly in Xenopus oocytes. These data suggest that the short form couples to a different effector system. Sequence analysis suggested that the two isoforms may arise from alternative pre-mRNA splicing. These results indicate that multiple forms of the human neurokinin-1 receptor exist and the differential activation of intracellular effector may be involved in generating the complex biological effects of substance P.

Citing Articles

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.


The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Covenas R, Rodriguez F, Robinson P, Munoz M Int J Mol Sci. 2023; 24(21).

PMID: 37958914 PMC: 10650658. DOI: 10.3390/ijms242115936.


Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies.

Isorna I, Gonzalez-Moles M, Munoz M, Esteban F J Clin Med. 2023; 12(19).

PMID: 37835053 PMC: 10573850. DOI: 10.3390/jcm12196409.


Association of Neurokinin-1 Receptor Signaling Pathways with Cancer.

Rodriguez F, Covenas R Curr Med Chem. 2023; 31(39):6460-6486.

PMID: 37594106 DOI: 10.2174/0929867331666230818110812.


Functional neuronal circuits promote disease progression in cancer.

Restaino A, Walz A, Vermeer S, Barr J, Kovacs A, Fettig R Sci Adv. 2023; 9(19):eade4443.

PMID: 37163587 PMC: 10171812. DOI: 10.1126/sciadv.ade4443.